About HCell Inc.
Hair Restoration MethodA Game-Changer |
HCell Treatment is a hair restoration method highly effective in returning a head of healthy, natural hair to those suffering from baldness and thinning. In over 400 patient treatments to date (South Korea), every patient treated with this short series of scalp injections is experiencing positive results—these outcomes are impressive and unmatched in the industry. To protect our innovation, we have secured U.S. patent approval and have applications pending with South Korea and the 140-country Patent Cooperative Treaty.
HCell Treatment is poised to be a major game-changer within the enormous market of potential consumers, more than 80 million men and women in the U.S. alone and billions worldwide. At least 60 percent (60%) of people will eventually suffer from hair loss and most report dissatisfaction with current treatments available. (See Figure Below)
Prescription medications (like Propecia) and surgical hair transplants (even those using stem-cell technology) do not deliver comparable results yet have dangerous risks or, at a minimum, messiness and unpleasant side effects. Similar-sounding, yet discerningly different, blood-based injectable methods often require more visits and yield less vigorous results than HCell Treatment. In addition, these therapies often use animal-based ingredients, a concern for some. However, our simple, in-office method is completely safe, convenient and, most significantly, delivers real and lasting results. |
Low Risk & CostBusiness OperationsInvestor Opportunity |
HCell Treatment will be marketed to consumers via a network of professional medical providers including highly reputable plastic surgeons, dermatologists and medical spas. Our licensee/franchisee business model minimizes corporate overhead and capitalizes on the professional reputations and deep patient pools of our providers. HCell Treatment is low in risk and cost, making it attractive and easy to incorporate into an existing practice or clinic.
HCell Inc. is currently in discussion to introduce new business operations in select countries via exclusive partnerships with established state-of-the-art clinics where regulatory restrictions do not impede. This parallel strategy along with engaging in the FDA regulatory approval process in the U.S. will help expedite HCell Inc.’s time-to-market. HCell Inc. is ramping up continued research and trials, business operations and sales and marketing and expects to be fully operational, with physicians trained and under license. An experienced management team will swiftly navigate the company through any obstacles and challenges standing in the way of reaching our $1.3B revenue estimates by the end of year five in full-scale operation. We are seeking prospective investors to help raise $8M in equity capital needed to launch initial business operations. Given the size of the global hair restoration market ($80 billion and growing) and our realistic, if not conservative, financial projections, investing in HCell Inc. is a low-risk and high-reward opportunity for the savvy, business-minded backer. |